Pfizer Logo

Pfizer Commences Consent Solicitation for Amendments to Wyeth Indenture

Thursday, October 15, 2009 - 07:00pm

(BUSINESS WIRE)--Pfizer today announced that it has commenced a consent solicitation to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary:

Debt Security Description	CUSIP No.	Aggregate Principal Amount
6.700% Notes due 2011	**026609AM**	**$1,497,580,000**
6.700% Notes due 2011	**026609AJ**	**$2,420,000**
5.250% Notes due 2013	**983024AA**	**$1,500,000,000**
5.500% Notes due 2014	**983024AE**	**$1,750,000,000**
5.500% Notes due 2016	**983024AJ**	**$1,000,000,000**
5.450% Notes due 2017	**983024AM**	**$500,000,000**
7.250% Notes due 2023	**026609AC**	**$250,000,000**
6.450% Notes due 2024	**983024AF**	**$500,000,000**
6.500% Notes due 2034	**983024AG**	**$750,000,000**
6.000% Notes due 2036	**983024AL**	**$500,000,000**

5.950% Notes due 2037 983024AN $2,000,000,000

Pfizer is soliciting consents from holders of record of the Securities as of 5:00 p.m. on October 14, 2009. In order for the proposed amendments to be adopted, consents must be received in respect of at least a majority in aggregate principal amount of Securities outstanding on the record date, with all series of Securities voting as a single class. If the proposed amendments are approved, Pfizer will (i) issue an unconditional and irrevocable guarantee of the prompt payment, when due, of any amounts owed in respect of the Securities and (ii) make a payment to each holder who validly delivers its consent prior to the expiration of the solicitation and does not revoke such consent of $1.50 for each $1,000 principal amount of Securities to which such consent relates. The solicitation will expire at 5:00 p.m., New York City time, on October 29, 2009, unless extended. The detailed terms and conditions of the consent solicitation are set forth in a Consent Solicitation/Prospectus Supplement dated October 16, 2009, which has been filed with the Securities and Exchange Commission, and related Letter of Consent, each to be sent to record holders of the Securities.

Barclays Capital. will act as Solicitation Agent for the consent solicitation. D.F. King will act as the Information Agent and Tabulation Agent. Copies of the Consent Solicitation/Prospectus Supplement may be obtained by contacting D.F. King by telephone at (800) 735-3591 (toll free) or (212) 269-5550 (banks and brokers). Questions regarding the Consent Solicitation/Prospectus Supplement may be directed to Barclays Capital at (800) 438-3242 (toll free) or (212) 528-7581.

This announcement is for informational purposes only and is not an offer to purchase or sell, a solicitation of an offer to purchase or sell, or a solicitation of consents with respect to any securities. The solicitation is being made solely pursuant to the above-described Consent Solicitation/Prospectus Supplement dated October 16, 2009 and the related letter of consent. -3-

The solicitation of consents is not being made in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such solicitation under applicable state or foreign securities or “blue sky” laws.

Pfizer Inc Media: Joan Campion, 212-733-2798 or Investors: Suzanne Harnett, 212-733-8009